drugset / Trial / NCT05673993
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.
Timeline
- Start
- 2023-04-06
- Primary completion
- 2024-10-29
- Completion
- 2025-05-06
Outcome
Met primary endpoint
release “achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren's disease.” vorbio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 80 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |